These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18567076)

  • 1. Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.
    Lu YP; Guo T; Wang BJ; Dong JH; Zhu JF; Liu Z; Lu MJ; Yang DL
    World J Gastroenterol; 2008 Jun; 14(22):3490-6. PubMed ID: 18567076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of novel HBV expression vectors in selecting antiviral drugs in clinical therapy].
    Lu YP; Dong JH; Liu Z; Guan SH; Lu MJ; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):8-12. PubMed ID: 17244450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
    Xu WZ; Fang Y; Li D; Wang Y; Shang QL; Li GQ; Teng X; Gu HX
    World J Gastroenterol; 2008 Jun; 14(23):3733-8. PubMed ID: 18595141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients.
    Ozekinci T; Mese S; Ozbek E; Atmaca S
    Clin Ter; 2014; 165(1):13-7. PubMed ID: 24589944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of chronic hepatitis B with primary adefovir resistance].
    Yamazhan T; Sertöz R; Pullukçu H; Taşbakan M; Ulusoy S; Erensoy S
    Mikrobiyol Bul; 2007 Apr; 41(2):297-301. PubMed ID: 17682718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
    Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
    Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
    Leemans WF; Janssen HL; Niesters HG; de Man RA
    J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir for lamivudine resistant HBV: more than meets the eye.
    Di Marco V; Craxì A
    J Hepatol; 2007 Oct; 47(4):618-9; author reply 619-20. PubMed ID: 17697727
    [No Abstract]   [Full Text] [Related]  

  • 14. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
    Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
    Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.